Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-199b mimic is a synthetic, double-stranded RNA oligonucleotide designed to simulate the biological activity of the endogenous microRNA miR-199b. As a microRNA mimic, it functions by binding to the 3' untranslated regions (UTRs) of target mRNAs, leading to translational inhibition or mRNA degradation. In various disease models, miR-199b has been identified as a tumor suppressor or immune modulator. Research indicates that miR-199b mimics can downregulate targets such as Cyclin L1 (CCNL1) in Ewing's sarcoma, Frizzled-6 in gastric cancer, and SET nuclear proto-oncogene in colorectal cancer. Additionally, in models of multiple sclerosis (experimental autoimmune encephalomyelitis), miR-199b mimics have been shown to inhibit CD44 expression and modulate cytokine production (IL-17 and IL-4), thereby suppressing lymphocyte proliferation and migration. These mimics are primarily used as research tools and are available from various life science suppliers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-199b mimic.